1
W French Anderson, R Michael Blaese, Steven A Rosenberg: Gene therapy. The United States of America represented by the Department of Health and Human Services, Elliot M Olstein, Raymond J Lillie, March 21, 1995: US05399346 (476 worldwide citation)

Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy.


2
Jack S Cohen, Len Neckers, Cy Stein, She L Loke, Kazuo Shinozuka: Inhibitors for replication of retroviruses and for the expression of oncogene products. The United States of America represented by the Department of Health and Human Services, Townsend and Townsend Khourie and Crew, November 23, 1993: US05264423 (373 worldwide citation)

Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.


3
Arthur M Krieg, Joel Kline, Dennis Klinman, Alfred D Steinberg: Immunostimulatory nucleic acid molecules. University of Iowa Research Foundation, Coley Pharmaceutical Group, The United States of America represented by the Department of Health and Human Services, Wolf Greenfield & Sacks P C, March 27, 2001: US06207646 (339 worldwide citation)

Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed.


4
Jack S Cohen, Len Neckers, Cy Stein, Shee L Loke, Kazuo Shinozuka: Inhibitors for replication of retroviruses and for the expression of oncogene products. The United States of America represented by the Department of Health and Human Services, James C Haight, Thomas Ferris, Julie Parker, January 4, 1994: US05276019 (339 worldwide citation)

Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.


5
Arthur M Krieg, Joel N Kline: Immunostimulatory nucleic acid molecules. University of Iowa Research Foundation, Coley Pharmaceutical Group, The United States of America represented by the Department of Health and Human Services, Wolf Greenfield & Sacks P C, May 29, 2001: US06239116 (322 worldwide citation)

Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant.


6
James F Brown, Jonathan E Silver, Olga V Kalinina: Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly. Cytonix Corporation, The United States of America represented by the Department of Health and Human Services, Kilyk & Bowersox P L L C, November 7, 2000: US06143496 (298 worldwide citation)

Methods of detecting and quantifying genomic nucleic acid molecule sequences are provided using the simultaneous amplification of a plurality of discrete nanoliter-sized samples. A miniaturized closed assembly is also provided for carrying out amplification of a nucleic acid molecule by polymerase c ...


7
Jack S Cohen, Len Neckers, Cy Stein, She L Loke, Kazuo Shinozuka: Inhibitors for replication of retroviruses and for the expression of oncogene products. The United States of America represented by the Department of Health and Human Services, Townsend and Townsend Khourie and Crew, February 15, 1994: US05286717 (293 worldwide citation)

Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.


8
Stephen E Epstein, Edith H Speir, Ellis F Unger: Inhibition of cell proliferation using antisense oligonucleotides. The United States of America represented by the Department of Health and Human Services, Townsend and Townsend and Crew, May 26, 1998: US05756476 (276 worldwide citation)

The present invention provides a method of inhibiting restenosis of a blood vessel in a mammal after mechanical treatment of the vessel to reduce a stenosis. The method includes contacting proliferating smooth muscle cells in the vessel with an antisense oligonucleotide directed against a cellular d ...


9
Josef Pitha: Pharmaceutical preparations containing cyclodextrin derivatives. The United States of America represented by the Department of Health and Human Services, John S Roberts Jr, February 23, 1988: US04727064 (268 worldwide citation)

The invention comprises pharmaceutical preparations consisting generally of a drug with a substantially low water solubility and an amorphous, water-soluble cyclodextrin-based mixtures. In these preparations a stable amorphous state can be achieved. This improves the dissolution properties of the dr ...


10
Barrie J Carter, Jon D Tratschin: Adeno-associated virus as eukaryotic expression vector. The United States of America represented by the Department of Health and Human Services, Holman & Stern, January 10, 1989: US04797368 (244 worldwide citation)

The present invention relates to a vector comprising part of AAV DNA contained in a plasmid and capable of being packaged into AAV particles and functioning as a vector for stable integration and expression of a gene in eukaryotic cells when under control of an AAV transcription promoter. A method o ...